🔎 Trials Near Me

Avaleht › Burkitti lümfoom › Kentucky

Burkitti lümfoom kliinilised uuringud osariigis Kentucky

5 uuringut haiguse Burkitti lümfoom jaoks otsivad osalejaid osariigis Kentucky.

Linnad osariigis Kentucky

Ametlik uuringutekst (inglise keeles)

A Study Testing the Combination of Dasatinib or Imatinib to Chemotherapy Treatment With Blinatumomab for Children, Adolescents, and Young Adults With Philadelphia Chromosome Positive (Ph+) or ABL-Class Philadelphia Chromosome-Like (Ph-Like) B-cell Acute Lymphoblastic Leukemia (B-ALL)

  • University of Kentucky/Markey Cancer Center, Lexington
  • Norton Children's Hospital, Louisville
VärbamineFaas 2
366 Days – 46 Years · Kõik sood · Uuendatud 2. okt 2026 · NCT06124157

Inotuzumab Ozogamicin and Frontline Chemotherapy in Treating Young Adults With Newly Diagnosed B Acute Lymphoblastic Leukemia

  • University of Kentucky/Markey Cancer Center, Lexington
VärbamineFaas 3
Vanused 18–39 · Kõik sood · Uuendatud 2. okt 2026 · NCT03150693

Testing the Addition of the Anti-cancer Drug Venetoclax and/or the Anti-cancer Immunotherapy Blinatumomab to the Usual Chemotherapy Treatment for Infants With Newly Diagnosed KMT2A-rearranged or KMT2A-non-rearranged Leukemia

  • University of Kentucky/Markey Cancer Center, Lexington
  • Norton Children's Hospital, Louisville
VärbamineFaas 2
365 Days · Kõik sood · Uuendatud 25. sept 2026 · NCT06317662

A Study to Compare Blinatumomab Alone to Blinatumomab With Nivolumab in Patients Diagnosed With First Relapse B-Cell Acute Lymphoblastic Leukemia (B-ALL)

  • University of Kentucky/Markey Cancer Center, Lexington
  • Norton Children's Hospital, Louisville
VärbamineFaas 2
Vanused 1–30 · Kõik sood · Uuendatud 1. sept 2026 · NCT04546399

Inotuzumab Ozogamicin and Post-Induction Chemotherapy in Treating Patients With High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and B-LLy

  • University of Kentucky/Markey Cancer Center, Lexington
  • Norton Children's Hospital, Louisville
VärbamineFaas 3
365 Days – 25 Years · Kõik sood · Uuendatud 25. aug 2026 · NCT03959085

Allikas ClinicalTrials.gov, andmed saadud 5. okt 2026. Igal uuringul on oma osalemiskõlblikkuse tingimused; uuringumeeskond otsustab, kes saab osaleda.